ANDA 203732, held by PH Health. Fluphenazine Decanoate.
As of Nov 21, 2026, ANDA 203732 (Fluphenazine Decanoate), held by PH Health, was first approved by FDA on Jul 3, 2014, with 3 approved supplements and 0 published complete response letters.
INDICATIONS AND USAGE Fluphenazine Decanoate Injection is a long-acting parenteral antipsychotic drug intended for use in the management of patients requiring prolonged parenteral neuroleptic therapy (e.g., chronic schizophrenics). Fluphenazine Decanoate Injection has not been shown effective in the management of behavioral complications in patients with mental retardation.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Jul 3, 2014 | Original application | Approved | None posted |
| Product | Active ingredient | Marketing |
|---|---|---|
| Fluphenazine Decanoate25MG/ML · injectable;injection | Fluphenazine Decanoate | Rx |
| Jan 22, 2025 | Supplement 13Labeling · Standard review | Approved | None posted |
| Feb 23, 2017 | Supplement 4Labeling · Standard review | Approved | None posted |
| Nov 18, 2016 | Supplement 3Labeling · Standard review | Approved | None posted |
| Jul 3, 2014 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. “What FDA's review says” is read by a model (Claude Haiku) from FDA's summary review PDF; a field is shown only if its numbers appear in the review, and each section links the review. Drugs@FDA and FDA complete response letters